WO2003105891A3 - Use of hec1 antagonists in the treatment of proliferative disorders and cancer - Google Patents

Use of hec1 antagonists in the treatment of proliferative disorders and cancer Download PDF

Info

Publication number
WO2003105891A3
WO2003105891A3 PCT/EP2003/006205 EP0306205W WO03105891A3 WO 2003105891 A3 WO2003105891 A3 WO 2003105891A3 EP 0306205 W EP0306205 W EP 0306205W WO 03105891 A3 WO03105891 A3 WO 03105891A3
Authority
WO
WIPO (PCT)
Prior art keywords
hec1
antagonists
cancer
treatment
proliferative disorders
Prior art date
Application number
PCT/EP2003/006205
Other languages
French (fr)
Other versions
WO2003105891A2 (en
Inventor
Erich A Nigg
Silvia Martin-Lluesma
Volker Stucke
Original Assignee
Max Planck Gesellschaft
Erich A Nigg
Silvia Martin-Lluesma
Volker Stucke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Erich A Nigg, Silvia Martin-Lluesma, Volker Stucke filed Critical Max Planck Gesellschaft
Priority to AU2003250831A priority Critical patent/AU2003250831A1/en
Priority to EP03759949A priority patent/EP1519736A2/en
Publication of WO2003105891A2 publication Critical patent/WO2003105891A2/en
Publication of WO2003105891A3 publication Critical patent/WO2003105891A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Abstract

The present invention relates to the use of (an) anti-HEC1 compound(s), (an) HEC1-complex antagonist(s) and/or (an) HEC1-complex inhibitor(s) for the preparation of a pharmaceutical composition for the prevention, amelioration and/or prevention of a hyperproliferative disorder/disease. Furthermore, the invention provides for a pharmaceutical composition comprising at least one anti-HEC1 compound, at least one HEC1-complex antagonist and/or at least one HEC1complex inhibitor. Additionally, the invention relates to a method for identifying an anti-Hec1 compound, an HEC1-complex antagonist or an HEC1-complex inhibitor.
PCT/EP2003/006205 2002-06-12 2003-06-12 Use of hec1 antagonists in the treatment of proliferative disorders and cancer WO2003105891A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003250831A AU2003250831A1 (en) 2002-06-12 2003-06-12 Use of hec1 antagonists in the treatment of proliferative disorders and cancer
EP03759949A EP1519736A2 (en) 2002-06-12 2003-06-12 Use of hec1 antagonists in the treatment of proliferative disorders and cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02013006 2002-06-12
EP02013006.8 2002-06-12

Publications (2)

Publication Number Publication Date
WO2003105891A2 WO2003105891A2 (en) 2003-12-24
WO2003105891A3 true WO2003105891A3 (en) 2004-05-06

Family

ID=29724387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/006205 WO2003105891A2 (en) 2002-06-12 2003-06-12 Use of hec1 antagonists in the treatment of proliferative disorders and cancer

Country Status (3)

Country Link
EP (1) EP1519736A2 (en)
AU (1) AU2003250831A1 (en)
WO (1) WO2003105891A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101234281B1 (en) 2004-04-09 2013-02-18 가부시키가이샤 진케어켄큐쇼 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
AU2006330084A1 (en) * 2005-09-30 2007-07-05 The Regents Of The University Of California SATB1: a determinant of morphogenesis and tumor metastatis
ES2537323T3 (en) 2007-08-20 2015-06-05 Oncotherapy Science, Inc. CDCA1 peptide and pharmaceutical agent comprising it
TWI526219B (en) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1 epitope peptides and vaccines containing the same
KR101609856B1 (en) 2010-03-17 2016-04-07 타이벡스 세라피틱스 코포레이션 Modulators of hec1 activity and methods therefor
SG10201506881PA (en) * 2011-11-21 2015-10-29 Taivex Therapeutics Corp Biomarkers for cancers responsive to modulators of hec1 activity
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
TWI640519B (en) 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Modulators of hec1 activity and methods therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045433A1 (en) * 1997-04-04 1998-10-15 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045433A1 (en) * 1997-04-04 1998-10-15 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEN Y ET AL: "HEC, A NOVEL NUCLEAR PROTEIN RICH IN LEUCINE HEPTAD REPEATS SPECIFICALLY INVOLVED IN MITOSIS", MOLECULAR AND CELLULAR BIOLOGY, WASHINGTON, DC, US, vol. 17, no. 10, 1 October 1997 (1997-10-01), pages 6049 - 6056, XP002068137, ISSN: 0270-7306 *
MARTIN-LLUESMA SILVIA ET AL: "Role of Hec1 in spindle checkpoint signaling and kinetochore recruitment of Mad1/Mad2", SCIENCE (WASHINGTON D C), vol. 297, no. 5590, 27 September 2002 (2002-09-27), pages 2267 - 2270, XP002263374, ISSN: 0036-8075 *
MOSS ERIC G: "RNA interference: It's a small RNA world", CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 11, no. 19, 2001, pages R772 - R775, XP002183121, ISSN: 0960-9822 *
UEDA R: "RNAI: A NEW TECHNOLOGY IN THE POST-GENOMIC SEQUENCING ERA", JOURNAL OF NEUROGENETICS, ELSEVIER, AMSTERDAM, NL, vol. 15, no. 3/4, 2001, pages 193 - 204, XP001147227, ISSN: 0167-7063 *
WIGGE PHILIP A ET AL: "Analysis of the Saccharomyces spindle pole by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry", JOURNAL OF CELL BIOLOGY, vol. 141, no. 4, 18 May 1998 (1998-05-18), pages 967 - 977, XP002263373, ISSN: 0021-9525 *
WIGGE PHILIP A ET AL: "The Ndc80p complex from Saccharomyces cerevisiae contains conserved centromere components and has a function in chromosome segregation", JOURNAL OF CELL BIOLOGY, vol. 152, no. 2, 22 January 2001 (2001-01-22), pages 349 - 360, XP002263372, ISSN: 0021-9525 *

Also Published As

Publication number Publication date
AU2003250831A1 (en) 2003-12-31
WO2003105891A2 (en) 2003-12-24
EP1519736A2 (en) 2005-04-06
AU2003250831A8 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
HK1086832A1 (en) Substituted benzosulphonamides as potentiators of glutamate receptors
MXPA05014166A (en) Methods and compositions for treating amyloid-related diseases.
EP1638950A4 (en) Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2006058236A3 (en) Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
WO2005037259A3 (en) Methods and compositions for the prevention or treatment of neoplasia comprising a cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
UA85041C2 (en) Method for ileus treating
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
NO20035025L (en) Use of osteopontin for the treatment and / or prevention of neurological diseases, as well as a pharmaceutical composition comprising osteopontin or an antagonist with osteopontin activity.
MXPA06000705A (en) Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders.
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
BRPI0511475A (en) combination, pharmaceutical composition, use of a combination, and method for treating cancer
IL162616A0 (en) Tetrahydroquinoline analogues as muscarinic agonists
SI1545537T1 (en) Alpha-7 nicotinic receptor agonists and statins in combination
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
BRPI0718469A2 (en) USE OF AN INTERLEUCIN 1 ANTAGONIST (IL-1), METHOD FOR TREATING, INHIBITING OR IMPROVING PSEUDOGOTA, USE OF ONE OR MORE THERAPEUTIC AGENTS, AND, PRODUCT.
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
WO2003105891A3 (en) Use of hec1 antagonists in the treatment of proliferative disorders and cancer
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2004026253A3 (en) Novel lapacho compounds and methods of use thereof
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
EA200601592A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PDE4 INHIBITOR OR PDE3 / 4 AND ANTAGONIST OF HISTAMINE RECEPTOR

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003759949

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003759949

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP